⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4337707 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL23854572 | 0.95 | — | — | |
| Formic Acid SCHEMBL31655727 | 0.91 | CHRNB2 (0.59) | — | |
| SCHEMBL2918867 | 0.90 | CHRNB2 (0.57) | — | |
| Trifluoroacetic Acid SCHEMBL29701070 | 0.85 | CHRNB2 (0.53) | — | |
| SCHEMBL21188142 | 0.83 | CHRNB2 (0.60) | — | |
| SCHEMBL18078663 | 0.83 | CHRNB2 (0.60) | — | |
| SCHEMBL2916439 | 0.81 | — | — | |
| SCHEMBL2977883 | 0.81 | CHRNB2 (1.00) | — | |
| SCHEMBL4125597 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | claimed |
| WO-2022058745-A9 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-27 | — | — | WO | claimed |
| CN-114222737-A | Small molecule inhibitor of NF-kB induced kinase | 詹森药业有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-20200109167-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2020-04-09 | — | — | US | claimed |
| EP-3601245-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents of The University of Michigan (US) | 2020-02-05 | — | — | EP | claimed |
| WO-2018183411-A1 | SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-10-04 | — | — | WO | claimed |
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2035409-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANATGONIST FOR THE CB1-RECEPTOR | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |